Table II.
Univariate and multivariate analysis of clinicopathological features and patient survival.
| 5-year DFS | 5-year OS | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Univariate analysis | ||||||
| Age | 1.00 | 0.96–1.04 | 0.908 | 1.00 | 0.95–1.06 | 0.868 |
| FIGO stage | 1.43 | 1.06–1.93 | 0.023 | 1.48 | 0.97–2.26 | 0.077 |
| Pathology | 1.66 | 0.74–3.69 | 0.237 | 1.68 | 0.54–5.21 | 0.392 |
| Histological grade | 1.49 | 0.88–2.51 | 0.129 | 1.86 | 0.85–4.09 | 0.104 |
| Tumor size (≤4 vs. >4 cm) | 2.71 | 1.26–5.87 | 0.007 | 1.79 | 0.65–4.93 | 0.251 |
| Depth of invasion (<2/3 vs. ≥2/3) | 5.58 | 2.29–13.56 | <0.001 | 9.12 | 2.07–40.16 | <0.001 |
| Parametrial invasion | 13.79 | 6.13–31.04 | <0.001 | 15.75 | 5.11–48.52 | <0.001 |
| LVSI | 3.31 | 1.51–7.21 | 0.006 | 1.16 | 0.26–5.16 | 0.849 |
| Lymph nodes metastases | 4.30 | 2.15–8.60 | <0.001 | 2.59 | 0.94–7.13 | 0.081 |
| Positive vaginal margin | 2.96 | 0.90–19.72 | 0.121 | 6.81 | 1.93–23.99 | <0.001 |
| PNI | 3.56 | 1.53–8.29 | 0.009 | 2.98 | 0.84–10.86 | 0.049 |
| Multivariate analysis | ||||||
| FIGO stage | 1.21 | 0.83–1.75 | 0.324 | – | – | |
| Tumor size (≤4 vs. > 4 cm) | 1.26 | 0.49–3.26 | 0.631 | – | – | |
| Depth of invasion (<2/3 vs. ≥2/3) | 3.04 | 1.17–7.88 | 0.022 | 5.85 | 1.23–27.80 | 0.026 |
| Parametrial invasion | 16.74 | 4.63–60.50 | <0.001 | 19.43 | 4.23–89.28 | <0.001 |
| LVSI | 2.22 | 0.98–5.04 | 0.057 | – | – | |
| Lymph node metastasis | 2.24 | 1.06–4.75 | 0.036 | – | – | |
| Positive vaginal margin | – | – | – | 3.14 | 0.78–12.57 | 0.106 |
| PNI | 0.26 | 0.07–0.91 | 0.056 | 0.28 | 0.05–1.59 | 0.154 |
DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; FIGO, International Federation of Gynecology and Obstetrics; PNI, perineural invasion; LVSI, lymphovascular space invasion.